STAAR Surgical Sees ICL Unit Growth Target Increase Of 30% Over FY18; Overall Revenue Target Expected To Be Impacted By Other Products Segment Sales Decline Of Approximately $3.60M, Including A $2.60M Reduction In Sales Of Low Margin Injector Parts
Benzinga Newsdesk